CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 25 enrolled
Drug / intervention
Clofarabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02425904
NCT02425904Phase 2Active
CompareCT.gov

Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Dana-Farber Cancer Institute·interventional·Posted Apr 24, 2015·Updated Jun 23, 2026

In Brief

A Phase 2 clinical trial evaluating Clofarabine for Langerhans Cell Histiocytosis. Active but no longer recruiting, targeting 25 participants across 15 sites in 2 countries.

Detailed Summary

This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLangerhans Cell Histiocytosis
CountriesCanada, United States
CollaboratorsSanofi, St. Baldrick's Foundation, Cookies for Kids' Cancer, North American Consortium for Histiocytosis

Timeline

Phase 2Active
2015201620172018201920202021202220232024202520262027
First PostedApr 24, 2015
Enrollment StartMay 1, 2015
Primary CompletionJan 1, 2020
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 11.2 years ago

Interventions

Clofarabinedrug

second-generation purine nucleoside analog